- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07595757
Effect of Nano-Hyaluronic Acid in Intrabony Defects Treated With Minimally Invasive Non-Surgical Technique
15. mai 2026 oppdatert av: Mustafa Hussein Alshebli, Cairo University
Clinical Evaluation of Nano-Hyaluronic Acid as an Adjunctive to Minimally Invasive Non-Surgical Technique in the Treatment of Deep Intrabony Defects: Randomized Controlled Clinical Trial
This randomized controlled clinical trial aims to evaluate the effectiveness of using nano-hyaluronic acid (nano-HyA) gel alongside a minimally invasive non-surgical technique (MINST) to treat deep intrabony defects in patients with Stage II and III periodontitis.
While MINST is a proven method for cleaning deep periodontal pockets without the need for traditional surgery , the addition of nano-HyA may further enhance soft tissue healing, reduce inflammation, and promote regeneration.
Participants in the study will be randomly assigned to one of two groups.
The test group will receive the MINST procedure combined with the application of nano-HyA gel into the periodontal pocket, while the control group will receive the MINST procedure alone.
The primary goal of the study is to measure the decrease in probing pocket depth over a 6-month follow-up period to determine if the adjunctive use of nano-HyA provides superior clinical and radiographic outcomes compared to non-surgical treatment alone
Studieoversikt
Status
Aktiv, ikke rekrutterende
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
28
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypt
- Faculty of Dentistry, Cairo University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Males and females aged ≥ 18 years.
- Patients with a diagnosis of periodontitis (stage II or III).
- At least one tooth with ≥5 mm PPD and CAL and evidence of radiographic bone loss.
- Presenting with at least 1 intrabony defect, with a radiographic intra-bony component ≥3 mm.
Exclusion Criteria:
- Patients with systemic diseases.
- Pregnant or lactating females.
- Tobacco smokers (≥ 10 cigarettes per day).
- Multi-rooted teeth with class II and class III furcation defects.
- Third molars.
- Teeth with grade III mobility.
- Peri-apical pathology and acute abscess.
- Non-surgical or surgical periodontal treatment in the past 12 months.
- Prolonged treatment with antibiotics or anti-inflammatory agents within 6 months before periodontal therapy.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: MINST alone
Participants receive the minimally invasive non-surgical technique (MINST) alone without adjunctive treatment
|
Subgingival debridement using thin ultrasonic tips and additional instrumentation with Gracey mini-curettes, deliberately avoiding subgingival rinsing to support blood clot stabilization
|
|
Eksperimentell: MINST + nano-hyaluronic acid
Participants receive MINST combined with adjunctive nano-hyaluronic acid
|
Subgingival debridement using thin ultrasonic tips and additional instrumentation with Gracey mini-curettes, deliberately avoiding subgingival rinsing to support blood clot stabilization
Pockets associated with intrabony defects are filled with nano-HyA paste immediately after subgingival debridement
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pocket Depth (PD)
Tidsramme: "From enrollment to the end of treatment at 24 weeks"
|
Measured in millimeters (mm) from the gingival margin to the bottom of the gingival sulcus using a UNC-15 periodontal probe.
Each tooth is probed at 6 sites with a light force not exceeding 25 grams.
|
"From enrollment to the end of treatment at 24 weeks"
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Full-Mouth Plaque Score (FMPS)
Tidsramme: From enrollment to the end of treatment at 24 weeks
|
Assessed as the percentage of sites with plaque.
|
From enrollment to the end of treatment at 24 weeks
|
|
Full-Mouth Bleeding Score (FMBS)
Tidsramme: From enrollment to the end of treatment at 24 weeks
|
Assessed as the percentage of sites with bleeding upon probing.
|
From enrollment to the end of treatment at 24 weeks
|
|
Clinical Attachment Level (CAL)
Tidsramme: From enrollment to the end of treatment at 24 weeks
|
Measured in millimeters (mm) from the cemento-enamel junction to the bottom of the pocket.
|
From enrollment to the end of treatment at 24 weeks
|
|
Gingival Recession (GR)
Tidsramme: From enrollment to the end of treatment at 24 weeks
|
Measured in millimeters (mm) from the cemento-enamel junction to the gingival margin.
|
From enrollment to the end of treatment at 24 weeks
|
|
Radiographic Defect Angle (RDA)
Tidsramme: From enrollment to the end of treatment at 24 weeks
|
Measured in degrees (°).
|
From enrollment to the end of treatment at 24 weeks
|
|
Patient Satisfaction
Tidsramme: From enrollment to the end of treatment at 24 weeks
|
Assessed via a Likert-scale questionnaire.
The scale ranges from 1 to 5, where 1 indicates "Very Dissatisfied" and 5 indicates "Very Satisfied".
Higher scores represent a better outcome.
|
From enrollment to the end of treatment at 24 weeks
|
|
Cost Effectiveness
Tidsramme: From enrollment to the end of treatment at 24 weeks
|
Evaluated through a health economic analysis, measured as currency per unit effect.
|
From enrollment to the end of treatment at 24 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
15. juli 2025
Primær fullføring (Antatt)
1. august 2026
Studiet fullført (Antatt)
29. august 2026
Datoer for studieregistrering
Først innsendt
11. mai 2026
Først innsendt som oppfylte QC-kriteriene
15. mai 2026
Først lagt ut (Faktiske)
19. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
19. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
15. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PER 3-3 -2
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .